Taken together, our findings suggested that distinct mechanisms underlie disruptions in the BCR-ABL+ and BCR-ABL− stem cells and the disruptions of BCR-ABL− stem cells of CML patients are associated with TKI response. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.